

1 **Title**

2

3 **scRNA-Seq reveals elevated interferon responses and TNF- α signaling via NF κ B in**
4 **monocytes in children with uncomplicated malaria**

5

6 **Authors:** Collins M. Morang'a¹, Riley S. Drake^{2,3,4,5}, Vincent N. Miao^{2,3,4,5}, Nancy K. Nyakoe¹,
7 Dominic S.Y. Amuzu¹, Vincent Appiah¹, Yaw Aniweh¹, Yaw Bediako¹, Saikou Y. Bah⁶, Alex
8 K. Shalek^{2,3,4,5}, Gordon A. Awandare¹, Thomas D. Otto^{6,*} & Lucas Amenga-Etego^{1,*}

9 **Affiliations**

10 ¹West African Centre for Cell Biology of Infectious Pathogens (WACCBIP), Department of
11 Biochemistry, Cell and Molecular Biology, University of Ghana, Legon, Accra, Ghana

12 ²Program in Health Sciences & Technology, Harvard Medical School & Massachusetts
13 Institute of Technology, Boston, MA 02115, USA

14 ³Institute for Medical Engineering & Science (IMES), Department of Chemistry, and Koch
15 Institute for Integrative Cancer Research, MIT, Cambridge, Massachusetts, 02139, USA

16 ⁴Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA

17 ⁵Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA

18 ⁶School of Infection & Immunity, MVLS, University of Glasgow, Glasgow, UK

19 *Correspondence thomasdan.otto@glasgow.ac.uk & lamengaetego@ug.edu.gh

20 **Abstract**

21 Malaria causes significant morbidity and mortality worldwide, disproportionately impacting
22 sub-Saharan Africa. Disease phenotypes associated with malarial infection can vary widely,
23 from asymptomatic to life-threatening. To date, prevention efforts, particularly those related
24 to vaccine development, have been hindered by an incomplete understanding of which
25 factors impact host immune responses resulting in these divergent outcomes. Here, we
26 conducted a field study in 224 malaria positive individuals (rapid diagnostic test - RDT) from
27 a high transmission area in Ghana, to determine immunological factors associated with
28 uncomplicated malaria “patients” compared to healthy individuals in the community
29 “controls”. Generally, the patients had higher parasite density levels although it had a
30 negative correlation with age, suggesting that, is a key indicator of disease pathogenesis.
31 We applied single-cell RNA-sequencing to compare the immunological phenotypes of 18,176
32 peripheral blood mononuclear cells (PBMCs) isolated from a subset of the patients and
33 controls (n=11/224), matched on location, age, sex, and parasite density. On average,
34 patients were characterized by a higher fractional abundance of monocytes and an
35 upregulation of innate immune responses, including those to type I and type II interferons
36 and tumor necrosis factor-alpha (TNF- α) signaling via NF κ B. Further, in the patients, we
37 identified more putative interactions between antigen-presenting cells and proliferating CD4
38 T cells and naïve CD8 T cells driven by MHC-I and MHC-II signaling pathways, respectively.
39 Together, these findings highlight transcriptional differences between immune cell subsets
40 associated with malaria that may help guide the development of improved vaccines and new
41 therapeutic interventions for individuals residing in endemic areas.

42

43

44

45

46 **Background**

47 In 2022, global estimates of malaria cases and deaths have increased to 249 million cases
48 and 608 000 deaths ¹. However, the development of an effective vaccine to address this
49 global health threat remains challenging due to an incomplete understanding of the parasite's
50 biology and limited knowledge of which host factors influence clinical responses to infection.

51 In malaria endemic communities, individuals may harbour malaria infections with mild to no
52 symptoms warranting treatment, here referred to as healthy community controls. Such
53 infections may be cleared naturally or progress to a uncomplicated malaria, where symptoms
54 become profound enough to necessitate medical intervention. Instructive factors include
55 environmental exposures, transmission intensity, host and parasite genetics, host-pathogen
56 interactions, and host immune responses ²⁻⁵. Illustratively, upregulation of interferon
57 responses and p53 gene expression can attenuate inflammation and protect children from
58 fever ⁶; and, when comparing children with asymptomatic and severe malaria, the genes
59 most upregulated in severe cases are related to immunoglobulin production and interferon
60 signaling ⁷. As reviewed previously, studies have postulated that interferons can orchestrate
61 immune regulatory networks to dampen inflammatory responses and restrict humoral
62 immunity, thus playing a critical role as a wedge that determines protection versus
63 permissiveness to malaria infection ^{8,9}.

64 Similarly, it has been shown that the number and phenotype of cells responding to infection
65 can vary with exposure to *Plasmodium* ¹⁰. For example, Africans, who tend to have higher
66 levels of exposure, have been shown to exhibit metabolic and platelet activation during
67 malaria infection as compared to typically infection-naïve Europeans ¹⁰. Similarly, children
68 who experience high cumulative malaria episodes show upregulation of interferon-inducible
69 genes and immunoregulatory cytokines, suggesting an immune modification to prevent
70 immunopathology and severe outcomes during new infections ¹¹. Beyond differences in
71 exposure and infection history, the strain responsible for each infection can also alter
72 immune response dynamics and disease pathogenesis ^{12,13}.

73 Since so many factors can influence host response dynamics to infection (e.g., exposure, the
74 timing of infection), some studies have implemented tightly regulated models of malarial
75 infection, such as controlled human-malaria infections (CHMI). CHMI studies have identified
76 several pathways, including toll-like receptor signaling ¹⁴, platelet activation ¹⁰, interferon
77 signaling ^{10,15,16}, and B-cell receptor signaling, that are involved in immunological modulation
78 of *Plasmodium falciparum* infections ⁶. Although CHMI enable more controlled examinations
79 of host-pathogen dynamics post-malaria infection, clinically relevant differences can arise
80 between responses seen in CHMI and natural exposure due to unresolved
81 immunopathological mechanisms elicited during *P. falciparum* infection ¹⁰. Thus, studies
82 involving natural cohorts provide a better avenue to understand variability in immune
83 responses developed through repeated exposure and how they influence disease
84 phenotypes. Besides, immunity to malaria develops very slowly through repeated infections,
85 and can wane quickly if individuals leave a malaria endemic areas, suggesting that
86 continuous natural exposure to malaria antigens is important for development of long term
87 immunity ¹¹. Collectively, these studies demonstrate the importance of obtaining a more

88 comprehensive understanding of the host and pathogen factors that influence immune
89 responses to inform the development of new therapeutic approaches and improved vaccines.

90 To date, most genomic analyses of immunological responses to malarial infection have been
91 performed in heterogeneous cell populations of blood, brain, liver, or spleen tissues¹⁷. The
92 majority of these studies have been conducted in children and the studies show that
93 symptomatic infections, as mentioned above, are characterized by upregulated expression of
94 genes involved in interferon signaling, antigen presentation, neutrophil-associated
95 signatures, and B cell modules relative to healthy controls¹⁷. Adults, meanwhile, present
96 slightly varying responses: symptomatic Malian adults, compared to naïve individuals, had
97 upregulated B cell receptor signaling but more modest upregulation of interferon responses,
98 while symptomatic Cameroonian adults showed marked induction of genes related to
99 interleukins and apoptosis compared to presymptomatic individuals^{18,19}. These
100 inconsistencies may be related to patient history/exposure or differences in cellular
101 composition influencing clinical course through a combination of direct and indirect
102 responses. The emergence of single-cell transcriptomics provides a unique opportunity to
103 examine the sources of this variability²⁰ by profiling abundance and transcriptomic variation
104 across immune cell populations in individuals with high malaria exposure but divergent
105 clinical phenotypes. Moreover, by examining the expression of ligands, receptors, and genes
106 involved in intercellular signaling, we can identify the critical mediators of immune responses
107 and the pathogenesis of malaria for subsequent validation²¹.

108 Here, we present a comparative analysis of peripheral blood mononuclear cells (PBMCs)
109 phenotypes in children from two related surveys conducted in 2019. An active case detection
110 of *P. falciparum* infections at the community level (controls) and passive case detection at
111 the health facility level for patients with uncomplicated malaria (patients) in an endemic area
112 in northern Ghana. Our data describe in unprecedented detail, cell subsets and signaling
113 pathways associated with disease severity to provide new insights into the immune response
114 mechanisms that influence the course of *P. falciparum* infections in young children.

115 Results

116 Clinical characteristics of study participants

117 In this study, we defined “controls” as healthy individuals who tested *Plasmodium* positive by
118 RDT in the community. We defined “patients” as individuals with uncomplicated malaria who
119 visited the hospital/health center from the same community and tested *Plasmodium* positive
120 by RDT and were treated on outpatient basis. All samples were collected from the same
121 region, Upper East region of Ghana which is a high transmission area. Overall, 224
122 individuals were surveyed, including 40% (90/224) of the participants who were community
123 healthy controls and 60% (134/224) of the participants who were patients with uncomplicated
124 malaria (**Figure 1a, Supplementary Table 1**). Although most participants were children
125 between 1-15 years, there was no significant difference between the median age of patients
126 compared to the controls (Wilcoxon rank-sum test, $P=0.74$) (**Supplementary Table 1**). But,
127 there was a significant difference in the median parasite density of patients compared to the
128 controls (Wilcoxon rank-sum test, $P<0.001$) (**Supplementary Table 1**). Further, the study
129 sought to determine if the patients had higher parasite densities than the controls regardless
130 of age. In general, there was negative correlation between parasite density and age
131 regardless of phenotype up to age 25 years (**Figure 1b**). Under 3 years, the patients tended
132 to have lower parasite densities, but these were still higher than their controls counterparts.
133 After about age 10 parasite densities fell gradually and plateaued around age 25 but with
134 high variability between the groups (**Figure 1b**). The correlation between parasite density
135 and malaria patients was statistically significant ($R^2 = -0.38$, $P<0.001$), but the correlation
136 between parasite density and age was not statistically significant in the control group (**Figure**
137 **1b**).

138 Profiling pediatric malaria immune-cell populations using single-cell analysis

139 In order to examine global differences in cellular composition, gene expression and
140 intercellular communication between the two groups, we matched individuals based on age
141 (aged 4-8 years), sex, and parasite density for both patients and controls and performed
142 single-cell RNA-seq (scRNA-seq) (**Figure 1a, Supplementary Table 2**). There was no
143 significant difference in median parasite density between patients and controls in the
144 matched individuals (Wilcoxon rank-sum test, $P>0.71$) (**Supplementary Table 2**). In total, we
145 generated 18,176 high-quality single-cell profiles across eleven children with *P. falciparum*
146 infections, allowing us to ascertain differences in expression patterns of immune response
147 genes that might influence disease pathogenesis. Each sample was profiled using Seq-Well
148 S³, a portable, simple massively parallel scRNA-Seq method²². The resulting data were
149 filtered to remove cells based on the fractional abundance of mitochondrial genes (<30%)
150 and transcripts expressing in <20 cells. After variable gene selection, dimensionality
151 reduction, clustering, cluster removal, and reclustering (**Methods**), we retained 18,303
152 transcripts and identified 10 distinct cell subsets in the 18,176 cells, across the two groups of
153 children (**Figure 1c; Supplementary Figure 1a**).

154 We manually annotated these 10 clusters using known RNA marker genes to identify B cells,
155 CD4 T cells, CD8 T cells, natural killer (NK) cells, monocytes (Mono), and dendritic cells
156 (DC) (**Supplementary Figure 1b and 1c**). To identify and enumerate cell subsets in our
157 dataset at higher resolution, we opted to map our query dataset to an annotated multimodal

158 reference dataset of PBMCs. First, we confirmed that all the cell subsets identified using
159 manual annotation were present in the resultant UMAP (**Supplementary Figure 1d**). As
160 expected, our reference mapped dataset recapitulated all PBMC subsets, including B, CD4 T
161 cells, CD8 T cells, NK cells, Mono, and DC (these subsets are used throughout the work;
162 **Figures 1c and 1d**). We identified several subclusters, such as intermediate, memory, and
163 naïve B cells; naïve, proliferating, effector memory and central memory CD8 and CD4 T
164 cells; proliferating CD56+ NK cells; CD14+ and CD16+ monocytes (Mono); plasmacytoid
165 (pDC) and conventional (cDC) dendritic cells, and other cell subsets (**Figures 1e and 1f**).
166 Since the reference dataset has only annotated two Mono clusters (CD14+ and CD16+), we
167 hypothesized that there might be additional transcriptional heterogeneity describing actively
168 responding Mono subpopulations. Therefore, further sub-clustering was done which resolved
169 the Mono into 3 large subpopulations (Mono 1, Mono 2, Mono 3) and 1 small cluster (Mono
170 4) (**Figures 1g, 1h and 1i**) based on previously reported markers²³. Taken together, these
171 data distinguish nearly all distinct cell subsets that were present in PBMCs of children in both
172 the patients and controls.

173 **Differences in relative cellular composition between the groups**

174 Next, we asked whether there were significant differences in the relative proportions of cell
175 types between the patients and control group. We found that relative cell proportions of the
176 major cell subsets (B, CD4 T, CD8 T, NK, Mono, and DC) varied between individuals in each
177 group (**Figures 2a and 2b, Supplementary Table 3**). The patients exhibited elevated levels
178 of circulating Mono while the controls had higher proportions of circulating B cells (Dirichlet-
179 multinomial regression, $P < 0.01$; **Figure 2a, Supplementary Table 3**). Further analysis of the
180 B cell subsets showed that the abundance of naïve and intermediate B cells was significantly
181 reduced in the patient group compared to the control group (Dirichlet-multinomial regression,
182 $P < 0.05$; **Figure 2b, Supplementary Table 3**). We also found a significant expansion of both
183 CD14+ and CD16+ Mono subsets in patients compared to the control group (Dirichlet-
184 multinomial regression, $P < 0.01$; **Figure 2b, Supplementary Table 3**). Although there is
185 evident variation in cellular proportions of T lymphocytes among all the individuals (**Figures**
186 **2a and 2b**), we did not observe any significant difference in proportions of either CD4 or CD8
187 T cells between the groups (Dirichlet-multinomial regression, $P > 0.05$; **Figure 2b,**
188 **Supplementary Table 3**). However, the proportions of naïve and central memory CD4 T
189 cells were significantly higher in the patients compared to the control group (Dirichlet-
190 multinomial regression, $P < 0.01$; **Figure 2b, Supplementary Table 3**). NK cell frequency was
191 also higher in patients suggesting that they may play a role in disease progression (Dirichlet-
192 multinomial regression, $P > 0.05$; **Figure 2b, Supplementary Table 3**). Among NK cells, the
193 proliferating and CD56+ subsets were higher in patients compared to controls, but these
194 differences were not statistically significant (Dirichlet-multinomial regression, $P > 0.05$; **Figure**
195 **2b, Supplementary Table 3**). Overall, the minor subsets of T cells and other cell types with
196 low frequencies did not show differences in proportions between the groups but the main cell
197 subsets had significant differences in proportions between patients and controls.

198 **Comparative analysis of inflammatory responses in children with malaria**

199 Having identified shifts in the composition of circulating immune cells between the patients
200 and controls, we next asked whether gene expression differed within each immune cell
201 subset between the two groups. Comparing patients to controls, we observed the largest

202 transcriptional changes (measured by pairwise DE across cell types with adjusted P value <
203 0.05 and log fold change > 2) within B cells and Mono (**Figures 2c, Supplementary Table**
204 **4**). Apart from B cell function genes, there was a general trend towards upregulation of
205 inflammatory genes in B and T cells in patients relative to control group, including *S100A8*,
206 *CXCL8*, and *S100A9* (**Figure 2c**). Significant transcriptional changes were also observed in
207 Mono, with genes such as *IFITM3*, *FCER1G*, and *CCL4* being upregulated in patients
208 compared to the control group (**Figure 2c**). Patients were also associated with the
209 upregulation of Major Histocompatibility Complex I (MHC-I) genes such as *HLA-A* and *HLA-*
210 *C* which are involved in antigen presentation in Mono (**Figure 2c**). In CD4 and CD8 T cells,
211 there was increased expression of some inflammatory factor signalling genes such as
212 *CXCL8* and *NFKBIA* in patients relative to the control group, suggesting direct sensing of
213 parasite products during clinical presentation (**Figure 2c**). Using gene set enrichment
214 analyses (GSEA), we found that the patients had robust induction of several innate immune
215 response pathways such as TNF- α signaling via NF- κ B, TGF- β signaling, IL6-JAK-STAT
216 pathway, complement, IL2-STAT5 signaling, inflammatory response, interferon- α response
217 (IFN- α), and interferon- γ response (IFN- γ) (**Figure 3a, Supplementary Table 5**). We
218 observed that although each cell type was enriched in one or more of these pathways, there
219 was a unique molecular signature of the genes involved in each. Upregulation of IFN- γ and
220 IFN- α response pathways in Mono were characterized by increased expression of genes
221 such as *IFITM2*, *IFITM3*, *IL10RA*, and *TNFAIP3*, while in NK cells they were typified by
222 genes such as *NFKBIA*, *CD69*, and *ISG20* (**Figure 3b & 3c, Supplementary Table 5**). Mono
223 and natural killer cells upregulated TNF- α signaling via the NF- κ B pathway with the induction
224 of genes related to this pathway such as *IL1B* and *TNFAIP3* for Mono, and *IL7R*, *CD44*, and
225 *NFKBIA* for NK cells (**Figure 3b & 3c, Supplementary Table 6**). Inflammatory responses in
226 Mono were characterized by *IL10RA*, *IL1B*, and *CXCL8* while in NK cells they were driven by
227 *CD69*, *IL7R*, *CXCL8*, and *NFKBIA* among others (**Figure 3b & 3c, Supplementary Table 5**).
228 Thus, the enrichment of unique genes for each cell subset for similar pathways suggests a
229 specific but concerted contribution of each cell subset toward the innate immune response in
230 patients.

231 **Relative enrichment of ISGs gene modules in monocytes of patients relative to** 232 **controls**

233 Since IFN genes were significantly upregulated in Mono patients relative to the control group,
234 we next sought to determine if entire gene modules were enriched. Interferon stimulated
235 genes (ISGs) modules scores were significantly higher in B cells, DC, CD4 T cells, and Mono
236 in patients compared to the control group (**Wilcoxon, adjusted $P < 0.01$ for all**
237 **comparisons, Figure 4a, 4b, 4d, and 4e**); however, there were no significant differences in
238 ISG module scores in CD8 T cells and NK cells. Further examination of intra- and inter-
239 individual variation in these module scores revealed substantial intra-individual variation in
240 cells from the same participant and between cells of the same type from different participants
241 (**Supplementary Figure 1e**). Overall, our data show that Mono play a significant role in
242 defining malaria patients compared to control participants from the same community through
243 induction of the ISGs gene modules.

244 Role of MHC-I and MHC-II signaling pathways in cell-to-cell interactions

245 Next, we used our single-cell data to infer putative axes of cell-to-cell communication using
246 signaling ligands, cofactors, and receptors. First, we discerned cell-to-cell interactions in the
247 patients and found that the number of interactions (ligand-receptor) originating from primary
248 innate immune cells such as DC and Mono were greater than those originating from non-
249 antigen presenting cells (**Supplementary Table 6**). However, our data show very few
250 inferred cellular communication networks in the control group (**Supplementary Table 6**).
251 This analysis suggests a role for Mono as antigen-presenting cells in orchestrating pro-
252 inflammatory responses by interacting with proliferating CD4 T cells, intermediate B cells,
253 effector memory T cells, and naïve CD8 T cells in the patient group (**Figure 5a**).
254 Conventional DC also produced factors that interact with proliferating and effector memory
255 CD4 T cells respectively, suggesting a concerted effort by antigen-presenting cells to activate
256 the immune response in patients (**Figure 5a**). Communication probabilities indicated that
257 MHC-I and MHC-II play a role in these interactions among other pathways. The most
258 significant receptor-ligand pairs for HLA-A, HLA-B, HLA-C, HLA-E, HLA-G, and HLA-F
259 ligands for MHC class I include CD8A, CD8B, LILRB2, and LILRB1 (**Figure 5b**). The leading
260 intercellular ligand-receptor pairs with CD4 T cells as signal receivers were distinct HLA
261 genes, with the highest relative contribution being driven by HLA-DRA and HLA-DRB1
262 (**Figure 5c**). The other minor signaling pathways that were important in patients include MIF,
263 RESISTIN, ANNEXIN, GALECTIN, ADGRE5, APP, CD22, CD45, SELPLG, CD99, CLEC,
264 and TNF signaling networks. For the TNF signaling pathway, the CD56⁺ NK cells showed to
265 be interacting with Mono and also with proliferating CD4 T cells, effector memory CD4 and
266 CD8 T cells, and cDC (**Figure 5d**). This cell communication network was mediated by *TNF* in
267 the sender cells and *TNFRSF1B* in the receiver subsets (**Figure 5e**), and this corroborates
268 the DE results (**Figure 5g**). We examined the expression levels of *TNFRSF1B* across all the
269 cell subsets and found that indeed it was expressed in all the receiver cells (**Figure 5f**). Only
270 the pDC and CD16 Mono showed cell-to-cell interactions with naïve and intermediate B cells
271 and might be playing a role in B cell activation and development in the control group through
272 MHC class II molecules (**Figure 5g and 5h**). Therefore, exposure of innate immune cells to
273 parasite ligands may potentially activate intracellular signaling cascades through cell-to-cell
274 interactions to induce rapid expression of a variety of innate immune genes.

275

276 Discussion

277 Here, we recruited 224 participants malaria from Navrongo, a high malaria transmission area
278 with seasonal fluctuations²⁴. Interestingly, most of participants indicated that they use long
279 lasting insecticide treated mosquito nets (LLINs), which helps to explain the low frequency of
280 infections; after screening 1,000 individuals in the community, <10% of them were positive
281 for *P. falciparum* as community healthy controls, suggesting a reduction in the malaria
282 infection reservoir. The National malaria elimination programme (NMEP) distributes LLINs as
283 part of strategy interventions, including community-based seasonal malaria chemoprevention
284 initiatives for children under 5 years in order to reduce the malaria burden in this area²⁴. The
285 ability of insecticide treated nets (ITNs) to interrupt malaria transmission has been shown in
286 large scale studies, which demonstrated that modern housing and ITNs could reduce malaria
287 infections by 1% and 16%, respectively²⁵. Further, we investigated the relationship between
288 age and parasite density, and found that parasite densities tended to decrease with age, but
289 the levels were generally higher in patients compared to controls in this high transmission
290 intensity area⁵.

291 To better understand cellular responses driving these divergent clinical phenotypes, we
292 performed scRNA-seq on PBMCs samples from eleven of the 224 individuals among the two
293 groups, controlling for group variability driven by age, fever and parasite density. This
294 enabled us to identify a potential role for interferon responses and TNF- α signaling via NF κ B
295 in Mono during the clinical manifestation of pediatric malaria infection. We also found
296 differences in the fractional abundances of PBMC cell subsets, with patients characterized by
297 a proportional increase in Mono while controls had a higher proportion of circulating B cells.
298 We showed cellular level variations in the expression of innate immune modules within and
299 between individuals as well as between clinical phenotypes. Further, we identified a role for
300 Mono and other innate immune cells through MHC-I and MHC-II molecules in driving cell-to-
301 cell interactions with CD8 and CD4 T cells respectively. Together, our work recontextualizes
302 the function of the innate immune cells in malaria, demonstrates how variable their
303 responses can be, and links specific acute phase response signaling pathways to clinical
304 presentation.
305

306 Differential gene expression comparing patients and controls across cell types revealed a
307 significant upregulation of genes associated with innate immunity in different cell types. We
308 show that CCL3 and CCL4 (also known as macrophage inflammatory protein MIP-1 α and
309 MIP-1 β respectively) were upregulated in Mono of patients, suggesting their possible role in
310 modulating clinical disease²⁶. CXCL8, the most potent human neutrophil attracting/activation
311 chemokine²⁷ was also highly upregulated in B cells, CD4, and CD8 T cells. Other studies
312 have shown that circulating levels of CXCL8 and CCL4 correlated with parasite density, and
313 when found in the cerebrospinal fluid they can predict cerebral malaria mortality^{13,28-30}.
314 Furthermore, the adaptive immune cell subsets (B cells and T cells) in the patient group
315 expressed two alarmins (S100A8 and S100A9) that are known to form calprotectin
316 heterodimer, an endogenous TLR4 ligand; this could suggest a possible role to silence
317 hyperinflammation³¹. We also show significant expression of FCER1G in B cells, Mono, and
318 DC in patients, which is induced by IFN- γ and encodes for a gamma chain of the FC receptor
319 and it is suggested to play an important role in controlling parasitemia⁶. Collectively, our data
320 imply that both adaptive and innate immune cells cooperatively play a role during the
321 pathogenesis of malaria in patients when compared to healthy controls.

322

323 We showed that several immune-related pathways are activated by *Plasmodium* infection
324 and disease including the TNF- α signaling via NF κ B pathway, IFN- α/γ responses, IL2-
325 STAT5 signaling, and inflammatory response pathway in patients. Since the parasite life
326 cycle involves repeated red cell invasion and rupture, the release of pyrogenic cytokines that
327 drive these pathways such as interleukins, interferons, and TNF in Mono and NK cells, can
328 signify pathophysiological events occurring in malaria patients^{13,32}. These observations could
329 also mean that children who patients were sampled quite early during the onset of the
330 disease progression trajectory¹². Our data are consistent with those previously described by
331 integrating whole blood transcriptomics, flow cytometry, and plasma cytokine analysis⁶, and
332 our results further identify the cell subsets in which these pathways were more enriched. We
333 show that each of the cell subsets has a unique signature of genes enriched in these
334 immunogenic pathways with minimal sharing. Several studies have shown similar innate
335 immune response pathways in individuals with malaria such as whole blood transcriptomics
336 of the Fulani of West Africa³³, children repeatedly exposed to malaria^{6,11}, controlled human
337 malaria infection (CHMI) studies¹⁶, and even mice models³¹. We have now confirmed some
338 of these observations and demonstrated that in the patient state, robust upregulation of
339 certain genes in specific cell subsets is associated with systemic inflammatory responses.
340 Innate immune cells, such as Mono, DC, and NK cells, appear to be most reactive in
341 patients, probably due to continuous exposure in a high transmission area as suggested by
342 other studies^{7,31,34}.

343

344 By collating gene modules of interferon-stimulated genes (ISGs), we show that there is a
345 differential expression between patients and controls across different cell subsets. ISGs are
346 normally produced as a function of interferon responses (IFNs)⁸, which we observe to be
347 enriched in patients. IFNs are produced primarily by DC to activate ISGs in other cells³⁵, and
348 we observed that B cells, T cells, Mono, and DC have higher ISG module scores in patients
349 compared to controls. Notably, our data show that each cell or cell subset responds
350 differently upon IFN activation with varying transcriptional responses of an ISG module
351 between individuals. This variability was also observed for cytokine modules, NF- κ B target
352 modules, and HLA modules. Similarly, a previous CHMI study observed striking inter-
353 individual variation in immune cell composition and immune responses, demonstrating that
354 an individual can have a unique immune fingerprint¹⁰. Thus, the variations in immune
355 responses that we observed could be attributed to the complexity of the *P. falciparum* life
356 cycle with several developmental erythrocytic stages, duration of infections, intensity of
357 infection in each individual, genetic factors, genetic variation in immune response genes
358 among other factors^{12,36}. These findings on inter-individual variability in immune responses
359 could provide insights when considering the design and evaluation of interventions that target
360 host immunity in the control of malaria.

361

362 Our scRNA-Seq data enabled us to quantitatively infer and analyze cell-to-cell
363 communication networks across all the innate and adaptive immune cells (Jin et al.,
364 2021). This analysis enabled us to uncover coordinated interactions between innate and
365 adaptive immune cells through various ligands. The cell-to-cell interactions in patients were
366 driven by MHC class I and II signaling pathways, whereby antigen-presenting cells were
367 shown to have more interactions with proliferating CD4 and naive CD8 T cells. The
368 importance of HLA genes has long been demonstrated by Hill and colleagues who
369 associated HLA-Bw53 antigen and DRB1*1302-DQB1*0501 haplotype to independently
370 protect against severe malaria in West Africa³⁷. Thus, our observations on cell-cell

371 interaction involving HLA molecules and T cells support the importance of these molecules
372 during *P. falciparum* infection and disease progression, consistent with the observed varying
373 degrees of interactions in patients compared to control groups. We also showed that within
374 patient group, there are contrasting interactions between various HLA I and HLA II molecules
375 with CD8 or CD4 T cell receptors respectively, which could be related to their tight regulation
376 and antigen-presenting ability^{38,39}. Activation of CD4 and CD8 T cells has been correlated
377 with protective immunity to malaria, and they can differentiate into several functionally distinct
378 subsets in the presence of various cytokines⁴⁰. It was not surprising that we identified
379 different fractional abundances of CD4 and CD8 T cell subsets in patients compared to
380 control group of children, but we demonstrate that ultimately this results in varying degrees of
381 interactions with Mono or DC. Future work should seek to identify the mechanisms that result
382 in these variations and their impact in orchestrating phagocytic and humoral responses as
383 this critical knowledge gap will be important in developing T cell-based malaria vaccines.

384 Overall, by using scRNA-seq on PBMCs obtained from patients and controls in a high
385 transmission area, this work sheds light on the interplay between peripheral immune cells
386 during uncomplicated malaria, uncovering the genes and immune pathways in specific cell
387 types that might play a significant role in defining the outcomes of infection. Data presented
388 here demonstrate that the patients with uncomplicated malaria were characterized by the
389 presence of inflammatory response signatures in specific cell types compared to the control
390 group. The results could also suggest that in the control group, a muted innate immune
391 response or disease tolerance mechanism plays a role in enabling children to harbour
392 malaria parasites in high malaria transmission areas without developing uncomplicated
393 malaria⁴¹. The findings are relevant for guiding the development of malaria vaccines, as well
394 as immunotherapeutics for alleviating uncomplicated malaria disease and preventing
395 progression to severe disease.

396

397

398 **Methods**

399 **Study design and sample collection**

400 In 2019, we conducted a cross-sectional active case detection survey in the Kassena-
401 Nankana Municipality of the Upper East Region of Ghana, to recruit children with
402 uncomplicated malaria and controls with *P. falciparum* infections. About 1000 community
403 members were screened for malaria infection using a CareStart™ PfHRP2-based malaria
404 Rapid Diagnostic Test (RDT, Access Bio, NY, USA). Positive cases in the community were
405 defined as “controls”, since these individuals hadn’t sought treatment within the past two
406 weeks. Similarly, a passive case detection of uncomplicated malaria cases was carried out
407 using the same mRDTs to screen individuals presenting at the Navrongo War Memorial
408 Hospital outpatient department. Individuals who tested positive for malaria and who provided
409 written informed consent were recruited into the study as defined as “patients”. Five milliliters
410 of whole blood was collected for PBMC isolation and for thick and thin blood smears for
411 parasite identification and quantification using microscopy. Linear regression models was
412 used to determine the relationship between parasite density and age in patients and controls
413 in R (version 4.2.1).

414

415 Of the 224 individuals recruited in both arms of the study, five control participants and six
416 patients were selected for single-cell transcriptomic analysis. Due to the observed clear
417 differences in clinical presentation between the groups driven by fever, headache and
418 parasite density, the 11 children selected for single-cell analysis had close similarity in these
419 factors. PBMCs were isolated in ACD tubes and spun at 2,000 revolutions per minute (rpm)
420 for 10 minutes, and the leukocytes layer was transferred to 15 mL. The leukocytes were
421 mixed with phosphate-buffered saline (PBS) and layered on 3 mL of lymphoprep in a 15 mL
422 falcon tube. The layered cells were spun for 30 minutes at 800 g without breaks and
423 harvested carefully by taking the buffy layer into another falcon tube. The PBMCs were
424 washed twice with PBS and stored in freezing media. During thawing, complete media
425 (RP10) with 20% Fetal Bovine Serum (FBS) was prepared by diluting 20 mLs of FBS in 80
426 mL of Roswellpark Memorial Institute (RPMI) media⁴². PBMCs were removed from Liquid
427 Nitrogen to the -80 °C freezer and then thawed during each experiment. Thawing was done
428 by placing the vial in a clean water bath at 37°C until a small crystal of frozen cells was
429 visible. The tubes were cleaned with 70% ethanol, and the contents were transferred to 10
430 mL of RP10 gently to minimise stressing the cells. The cells were centrifuged at 500g for 10
431 minutes and resuspended in RP10. Cell viability was estimated using Haemocytometer and
432 PBMCs were used after 1 hr of resting in the incubator at 37 °C.

433 **Seq-Well scRNA-Seq Workflow**

434 Seq-Well scRNA-Seq S³ workflow was performed according to the published methods^{22,43}.
435 In brief, 5x10⁵ PBMCs from each patient were dispensed into a single array containing
436 barcoded mRNA capture beads (Supplementary Figure 1). The arrays were sealed with a

437 Polycarbonate Track Etch (PCTE) membrane (pore size of 0.01 μ M), allowing cells to remain
438 separated through the lysis and hybridization steps. mRNA transcripts were hybridized and
439 recovered for reverse transcription using the Maxima H Minus Reverse Transcriptase in the
440 first strand synthesis step. Exonuclease (I) was used to remove excess primers and mRNA
441 was captured via poly-T priming of the poly-A mRNA. The captured mRNA underwent first-
442 strand synthesis to generate single-stranded cDNA while bound to the beads. Enzymes with
443 terminal transferase were used to create 3' overhangs and three cytosines. The overhangs
444 are used in template switching, whereby a SMART sequence is appended to the overhang
445 on both ends of the cDNA molecule during the first strand synthesis. Some templates fail to
446 switch, resulting in loss of the mRNA; hence they are chemically denatured using 0.1M
447 NaOH with random octamer with the SMART sequence in 5' orientation, and a second strand
448 is synthesized. Whole transcriptome amplification of the cDNA was performed using the
449 KAPA HiFi PCR master mix (Kapa Biosystems). Libraries were pooled and purified using
450 AgenCourt AMPure XP Beads. The quality of the library was assessed using Agilent Tape
451 Station with D5000 High Sensitivity tapes and reagents. Samples were barcoded as
452 described in the Nextera XT DNA (Illumina, USA) segmentation method. Tagmentation was
453 important because, after cDNA amplification and clean-up, there are usually very long cDNA
454 molecules that need to be fragmented to be sequenced by Illumina. The Nextera XT DNA
455 tagmentation method is effective and allows for the addition of adaptors and multiplex
456 indexes at both ends of each fragment²². Finally, the amplified library was purified using
457 SPRI beads, pooled, and sequenced using the NextSeq500 kit (Illumina, USA). Paired-end
458 sequencing was performed with a read structure of 20 bp read one, 50 bp read two, and 8 bp
459 index one as recommended for Seq-Well. The targeted sequencing depth was 100 million
460 reads for all samples.

461 **Processing sequencing reads**

462 The raw data were converted to demultiplexed FastQ files using bcl2fastq (Version 5, Terra
463 Workspace) using the Nextera XT indices and then aligned to the hg19 human genome
464 using STAR aligner (Version 2.7.9) within the Broad Institute DropSeq workflow (Version 11,
465 Terra Workspace). The data was cleaned using Cell Bender (V 0.2.0) with default settings, to
466 remove ambient RNA⁴⁴. The raw expression matrices and sample information were loaded
467 into the open-source statistical software R (R version 4.2.1). An array with 45,691 gene
468 features for 22,819 cells described data collected across 11 samples. The data were filtered
469 to include only features expressed in more than 20 cells, and the resultant matrix described
470 18,303 gene features across 22,819 cells. A Seurat (Version 4.0) object was created, and
471 the metadata was added to it to identify the participants⁴⁵. Cell cycle scoring was performed
472 and computation of the percentage of mitochondria genes before integration. The object from
473 each participant was transformed individually within the object using SCTransform followed
474 by the selection of integration features, finding the anchors, and finally combined integration.
475 Principal component analysis was performed to reduce the dimensionality of the data in
476 order to identify clusters of cells with similar transcriptomic profiles. Clusters and cluster
477 resolution were determined using FindNeighbors and a customized FindClusters function
478 that showed that the best resolution was 0.523, with an average silhouette score of: 0.2 and
479 11 clusters. One cluster showed no cluster-specific genes and was removed as multiplets,
480 leaving 18,176 cells. The remaining clusters were reclustered and re-embedded, resulting in
481 10 clusters with a resolution of 0.292, and an average silhouette score of: 0.301. The
482 average number of transcripts and expressed genes were evaluated per cluster using half

483 violin and boxplots. The clusters were projected to a two-dimensional space using the
484 Uniform Manifold Approximation and Projection (UMAP)⁴⁶ algorithm in Seurat.

485 **Reference-based mapping**

486 Immune cell subsets were identified using common cell markers to identify the Mono, T cells,
487 B cells, NK cells, DC, and other immune cell populations. Uniform Manifold Approximation
488 and Projection for Dimensional Reduction (UMAP) was used to embed the cell populations
489 and color code based on the expression of surface markers. The clustered PBMC dataset in
490 this study (query) was mapped to a reference CITE-Seq dataset of 162,000 PBMCs
491 measured with 228 antibodies⁴⁵. The query data were projected into the same dimensional
492 space as the reference dataset, thus separating the cells into the cell types present in the
493 reference dataset. The method first projected the reference data transformation onto the
494 query data, followed by the application of KNN-based identification of mutual nearest
495 neighbors (anchors) between the reference and query. On an L2-normalized dimensional
496 space, the reference data transferred continuous data onto the query data to annotate the
497 scRNA data based on a weighted vote classifier. For visualization, reference-based UMAP
498 embedding was used, considering that all the immune cell populations are well represented.

499 **Analyzing differences in samples**

500 Cluster/sample composition was calculated to determine the proportion of cells per cluster
501 and per cell type. Cell subsets that were significantly different between patient and control
502 groups were identified by computing Dirichlet Regression using the DirichReg function in
503 DirichletReg Package in R⁴⁷. Differentially expressed (DE) genes were computed using the
504 FindMarkers function on Seurat (Version 4.0), which we used to determine differentially
505 expressed genes in the patient and control groups using MAST with significance at ($P < 0.05$)
506 and log fold change of > 0.2 . Control 4 was not included in the DE analysis due to different
507 levels of cytokine module scores compared to the other controls participants
508 (**Supplementary Figure 1e**). DE genes were visualized using volcano-like plots and
509 heatmaps to compare all the cell types between patients and controls. The fgsea (R-
510 package) was used to analyze the pre-ranked gene set enrichment analysis (GSEA). Module
511 scores for HLA genes, ISG, NF κ B target genes, and cytokines were analyzed using the
512 AddModuleScore function in the Seurat R package. Statistical differences in module scores
513 between the patients and control groups for each cell subset was computed using Wilcoxon
514 sign-rank test with Bonferroni correction. Boxplots were used to visualize the module scores
515 for each cell, denoting the median and interquartile range.

516 **Cell-to-cell Interaction using CellChat**

517 CellChat (Version 1.1.1) was used to quantitatively infer and analyze cell-to-cell
518 communication networks²¹. Statistically significant intercellular communication between cell
519 groups was identified using permutation tests, and interactions with a significance level of
520 less than 0.05 were considered significant²¹. Heatmaps were used to visualize each
521 signaling pathway and their cell-cell communications, highlighting the number of interactions,
522 the sources (ligands) of the interactions, and the receivers (receptors) of the interactions.
523 The relative contribution of each ligand-receptor pair to the overall signaling was shown in
524 bar plots. The relative contribution provides a measure of a particular ligand-receptor

525 interaction in a particular cell-cell signaling network. This measure demonstrates the
526 importance or significance of the interaction in mediating cell communication between the
527 cell types and potential functional relationships. It is calculated by comparing the expression
528 levels of different cell receptor and ligand genes between the cell types while accounting for
529 all the possible interaction pairs within a signaling network.

530 **Acknowledgments**

531 We acknowledge the study participants for contributing to the study, and the staff of
532 Navrongo Health Research Centre, who provided support for this study. We are grateful to
533 Felix Ansah, Jersley Chirawurah, and Jonas Kengne, for their contributions to the data
534 collection and critical review of the work. All data were stored and analyzed on the University
535 of Ghana's high-performance computing system (Zuputo).

536 **Author's contributions**

537 G.A.A, TDO, LA, YB, and AKS contributed to design and conceptualization; CMM, LA, DA,
538 YA, and NKN contributed to sample collection and processing. VM, RD, and CMM
539 contributed to performing Seq-Well experiments; CMM performed the data analysis and
540 drafted the manuscript. VM, VA, SB, NKN, TDO, LA, and AKS contributed to data analysis
541 and drafting of the manuscript. All authors read and approved the manuscript.

542 **Funding**

543 The study was funded by a DELTAS Africa grant (DEL-15-007: Awandare). The DELTAS
544 Africa Initiative is an independent funding scheme of the African Academy of Sciences
545 (AAS)'s Alliance for Accelerating Excellence in Science in Africa (AESA) and supported by
546 the New Partnership for Africa's Development Planning and Coordinating Agency (NEPAD
547 Agency) with funding from the Wellcome Trust (107755/Z/15/Z: Awandare) and the UK
548 government. TDO was supported by the Wellcome Trust (104111/Z/14/Z & A). The study
549 was also supported by the Ragon Institute of MGH, MIT, and Harvard (AKS). The funders
550 had no role in the study design and interpretation of the results. The views expressed in this
551 publication are those of the author(s) and not necessarily those of AAS, NEPAD Agency,
552 Wellcome Trust, or the UK government.

553 **Availability of the data**

554 All data generated or analyzed during this study are included in this published article and its
555 supplementary information files. The scRNA-Seq data are available at [https://cellatlas-
556 cxg.mvls.gla.ac.uk/PBMC.Pediatric.Malaria.Ghana](https://cellatlas-cxg.mvls.gla.ac.uk/PBMC.Pediatric.Malaria.Ghana).

557 **Ethics approval and consent to participate**

558 Ethical clearance was obtained from the Noguchi Memorial Institute of Medical Research,
559 University of Ghana (**IRB 0000908**), and the Ghana Health Service (**GHS-ERC 008/02/19**).
560 All participants provided written informed consent before inclusion in the study.

561 **Consent for publication**

562 Not applicable.

563 **Competing interests**

564 A.K.S. reports compensation for consulting and/or SAB membership from Honeycomb
565 Biotechnologies, Cellarity, Ochre Bio, FL86, Relation Therapeutics, Senda Biosciences, Bio-
566 Rad Laboratories, IntraECate biotherapeutics, and Dahlia Biosciences unrelated to this work.

567 References

- 568 1. WHO. *World malaria report 2022*. World Health Organisation. (2022).
- 569 2. Babiker, H. A., Gadalla, A. A. H. & Ranford-Cartwright, L. C. The role of asymptomatic
570 *P. falciparum* parasitaemia in the evolution of antimalarial drug resistance in areas of
571 seasonal transmission. *Drug Resist. Updat.* **16**, 1–9 (2013).
- 572 3. Bousema, T., Okell, L., Felger, I. & Drakeley, C. Asymptomatic malaria infections:
573 Detectability, transmissibility and public health relevance. *Nat. Rev. Microbiol.* **12**,
574 833–840 (2014).
- 575 4. Nyarko, P. B. & Claessens, A. Understanding Host–Pathogen–Vector Interactions with
576 Chronic Asymptomatic Malaria Infections. *Trends Parasitol.* **37**, 195–204 (2021).
- 577 5. Ademolue, T. W., Aniweh, Y., Kusi, K. A. & Awandare, G. A. Patterns of inflammatory
578 responses and parasite tolerance vary with malaria transmission intensity. *Malar. J.*
579 **16**, (2017).
- 580 6. Tran, T. M. *et al.* A Molecular Signature in Blood Reveals a Role for p53 in Regulating
581 Malaria-Induced Inflammation. *Immunity* **51**, 750-765.e10 (2019).
- 582 7. Boldt, A. B. W. *et al.* The blood transcriptome of childhood malaria. *EBioMedicine* **40**,
583 614–625 (2019).
- 584 8. Mooney, J. P., Wassmer, S. C. & Hafalla, J. C. Type I Interferon in Malaria: A
585 Balancing Act. *Trends in Parasitology* vol. 33 257–260 (2017).
- 586 9. Sebina, I. & Haque, A. Effects of type I interferons in malaria. *Immunology* vol. 155
587 176–185 (2018).
- 588 10. de Jong, S. E. *et al.* Systems analysis and controlled malaria infection in Europeans
589 and Africans elucidate naturally acquired immunity. *Nat. Immunol.* **22**, 654–665
590 (2021).
- 591 11. Bediako, Y. *et al.* Repeated clinical malaria episodes are associated with modification
592 of the immune system in children. *BMC Med.* **17**, (2019).
- 593 12. Crompton, P. D. *et al.* Malaria immunity in man and mosquito: Insights into unsolved
594 mysteries of a deadly infectious disease. *Annu. Rev. Immunol.* **32**, 157–187 (2014).
- 595 13. Ioannidis, L. J., Nie, C. Q. & Hansen, D. S. The role of chemokines in severe malaria:
596 More than meets the eye. *Parasitology* **141**, 602–613 (2014).
- 597 14. Kazmin, D. *et al.* Systems analysis of protective immune responses to RTS,S malaria
598 vaccination in humans. *Proc. Natl. Acad. Sci. U. S. A.* **114**, 2425–2430 (2017).
- 599 15. Milne, K. *et al.* Mapping immune variation and var gene switching in naive hosts
600 infected with plasmodium falciparum. *Elife* **10**, 1–31 (2021).
- 601 16. Loughland, J. R. *et al.* Transcriptional profiling and immunophenotyping show
602 sustained activation of blood monocytes in subpatent Plasmodium falciparum
603 infection. *Clin. Transl. Immunol.* **9**, e1144 (2020).
- 604 17. Lee, H. J. *et al.* Transcriptomic Studies of Malaria: a Paradigm for Investigation of
605 Systemic Host-Pathogen Interactions. *Microbiol. Mol. Biol. Rev.* **82**, (2018).
- 606 18. Tran, T. M. *et al.* Transcriptomic evidence for modulation of host inflammatory
607 responses during febrile Plasmodium falciparum malaria. *Sci. Rep.* **6**, 1–12 (2016).
- 608 19. Ockenhouse, C. F. *et al.* Common and divergent immune response signaling
609 pathways discovered in peripheral blood mononuclear cell gene expression patterns in
610 presymptomatic and clinically apparent malaria. *Infect. Immun.* **74**, 5561–5573 (2006).
- 611 20. Hie, B. *et al.* Computational Methods for Single-Cell RNA Sequencing. *Annu. Rev.*
612 *Biomed. Data Sci.* **3**, 339–364 (2020).
- 613 21. Jin, S. *et al.* Inference and analysis of cell-cell communication using CellChat. *Nat.*
614 *Commun.* **12**, 1–20 (2021).
- 615 22. Hughes, T. K. *et al.* Second-Strand Synthesis-Based Massively Parallel scRNA-Seq
616 Reveals Cellular States and Molecular Features of Human Inflammatory Skin
617 Pathologies. *Immunity* **53**, 878-894.e7 (2020).

- 618 23. Villani, A. C. *et al.* Single-cell RNA-seq reveals new types of human blood dendritic
619 cells, monocytes, and progenitors. *Science (80-.).* **356**, (2017).
- 620 24. Amenga-Etego, L. N. *et al.* Temporal evolution of sulfadoxine-pyrimethamine
621 resistance genotypes and genetic diversity in response to a decade of increased
622 interventions against *Plasmodium falciparum* in northern Ghana. *Malar. J.* **20**, 152
623 (2021).
- 624 25. Tusting, L. S. *et al.* Housing Improvements and Malaria Risk in Sub-Saharan Africa: A
625 Multi-Country Analysis of Survey Data. *PLoS Med.* **14**, (2017).
- 626 26. Awandare, G. A. *et al.* Increased levels of inflammatory mediators in children with
627 severe *Plasmodium falciparum* malaria with respiratory distress. *J. Infect. Dis.* **194**,
628 1438–1446 (2006).
- 629 27. Cambier, S., Gouwy, M. & Proost, P. The chemokines CXCL8 and CXCL12: molecular
630 and functional properties, role in disease and efforts towards pharmacological
631 intervention. *Cell. Mol. Immunol.* **20**, 217–251 (2023).
- 632 28. Abrams, E. T. *et al.* Host Response to Malaria During Pregnancy: Placental Monocyte
633 Recruitment Is Associated with Elevated β Chemokine Expression. *J. Immunol.* **170**,
634 2759–2764 (2003).
- 635 29. Armah, H. B. *et al.* Cerebrospinal fluid and serum biomarkers of cerebral malaria
636 mortality in Ghanaian children. *Malar. J.* **6**, 1–17 (2007).
- 637 30. Ayimba, E. *et al.* Proinflammatory and regulatory cytokines and chemokines in infants
638 with uncomplicated and severe *Plasmodium falciparum* malaria. *Clin. Exp. Immunol.*
639 **166**, 218–226 (2011).
- 640 31. Nahrendorf, W., Ivens, A. & Spence, P. J. Inducible mechanisms of disease tolerance
641 provide an alternative strategy of acquired immunity to malaria. *Elife* **10**, (2021).
- 642 32. Gazzinelli, R. T., Kalantari, P., Fitzgerald, K. A. & Golenbock, D. T. Innate sensing of
643 malaria parasites. *Nat. Rev. Immunol.* **14**, 744–757 (2014).
- 644 33. Quin, J. E. *et al.* Major transcriptional changes observed in the Fulani, an ethnic group
645 less susceptible to malaria. *Elife* **6**, (2017).
- 646 34. Gray, J. C. *et al.* Profiling the antibody immune response against blood stage malaria
647 vaccine candidates. *Clin. Chem.* **53**, 1244–1253 (2007).
- 648 35. Spaulding, E. *et al.* STING-Licensed Macrophages Prime Type I IFN Production by
649 Plasmacytoid Dendritic Cells in the Bone Marrow during Severe *Plasmodium yoelii*
650 Malaria. *PLoS Pathog.* **12**, e1005975 (2016).
- 651 36. Awandare, G. A. *et al.* MIF (Macrophage Migration Inhibitory Factor) promoter
652 polymorphisms and susceptibility to severe malarial anemia. *J. Infect. Dis.* **200**, 629–
653 637 (2009).
- 654 37. Hill, A. V. S. *et al.* Common West African HLA antigens are associated with protection
655 from severe malaria. *Nature* **352**, 595–600 (1991).
- 656 38. Guermonprez, P., Valladeau, J., Zitvogel, L., Théry, C. & Amigorena, S. Antigen
657 presentation and T cell stimulation by dendritic cells. *Annu. Rev. Immunol.* **20**, 621–
658 667 (2002).
- 659 39. Rock, K. L., Reits, E. & Neefjes, J. Present Yourself! By MHC Class I and MHC Class
660 II Molecules. *Trends Immunol.* **37**, 724–737 (2016).
- 661 40. Kurup, S. P., Butler, N. S. & Harty, J. T. T cell-mediated immunity to malaria. *Nat. Rev.*
662 *Immunol.* **19**, 457–471 (2019).
- 663 41. Nideffer, J. *et al.* Disease Tolerance Acquired Through Repeated *Plasmodium*
664 Infection Involves Epigenetic Reprogramming of Innate Immune Cells. *bioRxiv*
665 2023.04.19.537546 (2023) doi:10.1101/2023.04.19.537546.
- 666 42. Hønge, B. L., Petersen, M. S., Olesen, R., Møller, B. K. & Erikstrup, C. Optimizing
667 recovery of frozen human peripheral blood mononuclear cells for flow cytometry. *PLoS*
668 *One* **12**, 1–17 (2017).
- 669 43. Gierahn, T. M. *et al.* Seq-Well: Portable, low-cost rna sequencing of single cells at
670 high throughput. *Nat. Methods* **14**, 395–398 (2017).
- 671 44. Fleming, S. J., Marioni, J. C. & Babadi, M. CellBender remove-background: A deep
672 generative model for unsupervised removal of background noise from scRNA-seq
673 datasets. *bioRxiv* 791699 (2019) doi:10.1101/791699.

- 674 45. Hao, Y. *et al.* Integrated analysis of multimodal single-cell data. *Cell* **184**, 3573-
675 3587.e29 (2021).
676 46. McInnes, L., Healy, J. & Melville, J. UMAP: Uniform Manifold Approximation and
677 Projection for Dimension Reduction. (2018).
678 47. Simmons, S. Cell Type Composition Analysis: Comparison of statistical methods.
679 *bioRxiv* 2022.02.04.479123 (2022).
680
681

Figures

682 **Figure 1 | Analysis of scRNA-Seq data from uncomplicated malaria patients and**
683 **community healthy controls. a)** Experimental flow showing that PBMCs were collected
684 from eleven individuals out of 224 based on the modelling and matching the patients and
685 controls by age, sex, and parasite density. **b)** Regression analysis between parasite density
686 and age for patients (grey) and controls (blue). **c)** Uniform manifold approximation and
687 projection (UMAP) plot of 22,819 cells from eleven participants colored by identities of 10 cell
688 clusters; mainly B cells, T cells, and Mono. **d)** Expression levels of cluster-defining marker
689 genes organized by color intensity to show the average expression of the marker in that
690 particular cell type and the proportion of cells with non-zero expression shown by the size of
691 the dot. **e)** Markers used to annotate the subclusters to various cell subsets showing
692 average expression and fraction of cells expressing the marker. **f)** Reference mapped
693 dataset showing the predicted subclusters of B, CD4 T, CD8 T, NK, Mono, and DC cell
694 subsets. Reference-defined cell subsets were generated from CITE-seq reference of
695 162,000 PBMCS measured using 228 antibodies ⁴⁵. **g)** UMAP of re-clustered and re-
696 embedded Mono showing four subclusters of the CD14 and CD16 Mono. **h)** Markers used to
697 identify monocyte subclusters. **i)** Mono top 10 highly expressed genes in each subcluster.

698 **Figure 2 | Profiling of immune cells from patients compared to the controls. a).**
699 Relative cell proportions of the major cell subsets within patients and control groups.
700 Statistical tests were conducted using the Dirichlet Multinomial Regression in the
701 DirichletReg package in R ⁴⁷. The dots represent individual proportions while the color
702 scheme represents the patients and control groups. **b)** Relative proportions of minor cell
703 subsets compared between patients and controls. Cell proportions per group and P-value are
704 shown in **Supplementary Table 1**. **c)** Violin-like plots showing genes that are differentially
705 expressed between patients and controls. The x-axis shows the Log₂ fold change against the
706 cell subsets (y-axis) – i.e., B cells, Mono, CD4 T cells, CD8 T cells, other T cells, dendritic
707 cells (DC) and natural killer (NK) cells. The color scheme is based on the upregulated (up
708 patients) and downregulated (down patients) genes in patients and the size of the point
709 represents the adjusted P value. The frequency shows the number of comparisons in which
710 the gene is significantly expressed in the cell subset.

711 **Figure 3 | Pathway analysis using geneset enrichment method a)** Pathway analysis
712 using an immunologic signature geneset enrichment analysis (GSEA) and the color scheme
713 is based on the normalized enrichment score of genes DEG in patients. **b)** Dot plots showing
714 some of the leading edge genes in IFN- γ and IFN- α response, TNF- α signaling via NF κ B &
715 inflammatory response pathways in Mono and, **c)** NK cells. Dot size represents the fraction
716 of cell subsets expressing a given gene. The dot color indicates scaled average expression
717 by gene column.

718 **Figure 4 | Module score analysis of innate immune gene modules.** **a)** Boxplot showing
719 interferon-stimulated gene (ISG) module scores per cell subset compared between patients
720 and controls in **B cells**, **b)** CD4 T cells, **c)** CD8 T cells, **d)** DC **e)** Mono, **f)** NK cells. Module
721 scores are computed using the AddModuleScore function in the Seurat R package.
722 Statistical significance between the patients and controls of each cell subset was computed
723 using Wilcoxon sign-rank test with Bonferroni correction. Non significant differences are
724 indicated by ns.

725 **Figure 5 | Primary innate immune cells dominate the cell-to-cell interactions with other**
726 **cell subsets.** **a)** Heatmap showing the number of interactions between the PBMCs cell
727 subsets. The y-axis shows the signal senders and the x-axis shows the signal receivers. **b)**
728 Relative contribution of ligand receptor pairs in patients within the MHC class I signaling
729 pathway and **(c)** MHC class II signaling networks, respectively. A higher relative contribution
730 indicates the magnitude of contribution of the ligand-receptor and its significant role in the
731 MHC I or II signalling networks. **d)** Cell communications through the TNF signaling pathway
732 and the arrows indicate signal sender to receiver. **e)** Relative contribution of the TNF-
733 TNFRSF1B ligand-receptor pair towards the TNF signaling pathway. **f)** Violin plots showing
734 the expression levels of the TNFRSF1B in the Seurat object for the cell subclusters. **g)**
735 Heatmap comparison showing the overall signaling between all cell subclusters and the
736 number of interactions. **h)** Relative contribution of MHC class II signaling pathway in the
737 control group.

738 **Supplementary Figure 1 | Cluster identification and annotation.** **a)** UMAP of 22,819 cells
739 from all participants, showing 10 clusters in the dataset (following iterative Louvian
740 clustering). **b)** Dot plots showing genes used to manually annotate the clusters and show the
741 fraction of cells expressing it and the non-zero expression. Dot size represents the fraction of
742 cell types (rows) expressing a given gene (columns). The dot color indicates scaled average
743 expression by gene column. **c)** UMAP colored by various manually annotated clusters based
744 on the cell markers **d)** UMAP showing cell clusters identified from a reference-mapped
745 dataset but labeled with the manually annotated cluster identities. **e)** Heatmap showing
746 overall module score for each cell, and grouped based on each participant and all the cell
747 types, and overall study groups. The color scheme represents a scale for module scores.

748
749 **Supplementary Tables**

750
751 **Supplementary Table 1:** Descriptive statistics of all study participants

752 **Supplementary Table 2:** Descriptive statistics of matched study participants for scRNA-Seq

753 **Supplementary Table 3:** Dirichlet regression analysis of proportions of various cell types
754 compared between the two groups

755 **Supplementary Table 4:** Differentially expressed genes between patients and controls









756 **Supplementary Table 5:** Pathway analysis of differentially expressed genes between
757 patients and control group




758 **Supplementary Table 6:** Leading pathways in cell-cell interaction analysis for the patient
759 group




760 **Supplementary Table 7:** Leading pathways in cell-cell interaction analysis for the control
761 group


762

763












a Cell-cell interactions in patients




b MHC class I interactions




c MHC class II interactions




e TNF signalling interactions




d TNF signaling pathway network



f TNFRSF1B



g Cell-cell interactions in Controls



h MHC class II interactions in Controls

